Program
Anti-PTK7 Antibody-drug Conjugate HWK-007
Its studies are mostly in Endometrial Neoplasms, led by Whitehawk Therapeutics.
Furthest: phase 1, since Feb 11, 20261 company-led study, 1 open or runningNext primary completion: Oct 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Whitehawk Therapeutics | 11 open or running | phase 1since Feb 11, 2026 | Feb 11, 2026 | Oct 2028phase 1 · NCT07444814 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 11, 2026First study: phase 1 study in Endometrial NeoplasmsFirst studyNCT07444814 · 226 planned · United States
Ahead
- Oct 2028Primary completion: phase 1 study in Endometrial NeoplasmsNCT07444814
TargetBeta
PTK7 →read by rule
“An antibody-drug conjugate (ADC) composed of an antibody directed against human inactive tyrosine-protein kinase 7 (protein tyrosine kinase 7; PTK7) ”NCIt, by rule
Other programs on PTK7
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-PTK7 Antibody-drug Conjugate SKB518rule | Sichuan Kelun Pharmaceutical | phase 2 | 3 |
| Anti-PTK7/Exatecan Antibody-drug Conjugate DAY301rule | day-one-biopharmaceuticals-inc | phase 1 | 1 |
| Anti-PTK7/Exatecan Antibody-drug Conjugate LY4175408rule | Eli Lilly | phase 1 | 1 |
| Anti-B7-H3/Anti-PTK7-TOP1i Bispecific Antibody-drug Conjugate IDE034rule | ideaya-biosciences | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07444814Endometrial Neoplasms · United States | 1 | Recruiting | Oct 2028 | 226 |
How it is read
Names in the registry
- “HWK-007”, 1 entry
Conditions, from the studies’ own filings
- Endometrial Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.